17,587 Shares in Celgene Co. (CELG) Purchased by B. Riley Wealth Management Inc.

Share on StockTwits

B. Riley Wealth Management Inc. purchased a new position in Celgene Co. (NASDAQ:CELG) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 17,587 shares of the biopharmaceutical company’s stock, valued at approximately $1,574,000.

Several other institutional investors have also recently made changes to their positions in the company. Dimensional Fund Advisors LP raised its stake in shares of Celgene by 1.5% during the second quarter. Dimensional Fund Advisors LP now owns 1,870,847 shares of the biopharmaceutical company’s stock worth $148,556,000 after acquiring an additional 27,542 shares in the last quarter. FMR LLC raised its stake in shares of Celgene by 14.8% during the second quarter. FMR LLC now owns 8,160,001 shares of the biopharmaceutical company’s stock worth $648,067,000 after acquiring an additional 1,051,528 shares in the last quarter. Ontario Teachers Pension Plan Board raised its stake in shares of Celgene by 5.7% during the second quarter. Ontario Teachers Pension Plan Board now owns 141,882 shares of the biopharmaceutical company’s stock worth $11,268,000 after acquiring an additional 7,609 shares in the last quarter. Northwestern Mutual Wealth Management Co. raised its stake in shares of Celgene by 4.6% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 53,157 shares of the biopharmaceutical company’s stock worth $4,222,000 after acquiring an additional 2,348 shares in the last quarter. Finally, Highstreet Asset Management Inc. raised its stake in shares of Celgene by 7.8% during the second quarter. Highstreet Asset Management Inc. now owns 44,197 shares of the biopharmaceutical company’s stock worth $3,510,000 after acquiring an additional 3,206 shares in the last quarter. 72.80% of the stock is currently owned by hedge funds and other institutional investors.

Several research firms have commented on CELG. Zacks Investment Research raised shares of Celgene from a “sell” rating to a “hold” rating in a research note on Monday, December 31st. Canaccord Genuity downgraded shares of Celgene from a “buy” rating to a “hold” rating in a research note on Thursday, January 3rd. Leerink Swann downgraded shares of Celgene from an “outperform” rating to a “market perform” rating in a research note on Thursday, January 3rd. ValuEngine raised shares of Celgene from a “strong sell” rating to a “sell” rating in a research note on Friday, January 4th. Finally, BidaskClub raised shares of Celgene from a “strong sell” rating to a “sell” rating in a research note on Friday, January 4th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Celgene currently has a consensus rating of “Buy” and a consensus target price of $111.78.

CELG stock traded down $0.07 during trading on Wednesday, reaching $87.51. The company had a trading volume of 11,603,500 shares, compared to its average volume of 28,636,148. The company has a debt-to-equity ratio of 4.06, a current ratio of 2.13 and a quick ratio of 1.99. The company has a market cap of $59.37 billion, a P/E ratio of 12.79, a PEG ratio of 0.43 and a beta of 1.44. Celgene Co. has a 52 week low of $58.59 and a 52 week high of $107.29.

Celgene (NASDAQ:CELG) last announced its earnings results on Thursday, October 25th. The biopharmaceutical company reported $2.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.02 by $0.27. The firm had revenue of $3.89 billion during the quarter, compared to analyst estimates of $3.83 billion. Celgene had a return on equity of 108.76% and a net margin of 19.64%. On average, equities research analysts expect that Celgene Co. will post 7.45 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “17,587 Shares in Celgene Co. (CELG) Purchased by B. Riley Wealth Management Inc.” was originally reported by Fairfield Current and is the property of of Fairfield Current. If you are reading this piece on another domain, it was illegally stolen and republished in violation of US and international copyright legislation. The original version of this piece can be accessed at https://www.fairfieldcurrent.com/news/2019/01/10/b-riley-wealth-management-inc-invests-1-57-million-in-celgene-co-celg.html.

Celgene Profile

Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Featured Story: What impact do institutional investors have on markets?

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply